top of page
The Professional Network for Healthcare Experts
Merck KGaA agrees $1.3 billion acquisition of Silence Therapeutics to expand rare disease siRNA pipeline
Merck KGaA has agreed to acquire Silence Therapeutics in an all-cash transaction valued at approximately $1.3 billion in equity, expanding its RNA interference pipeline.
nuaxia
2 days ago2 min read
Merck KGaA Expands Life Sciences Business with $11.3bn Bio-Techne Acquisition
Merck KGaA has agreed to acquire US-based life sciences company Bio-Techne, significantly expanding its presence across the life sciences value chain.
nuaxia
Jun 303 min read
bottom of page